Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Granulocyte macrophage-colony stimulating factor (GM-CSF) blockade and that of its receptor are effective in inflammatory arthritis models and rheumatoid arthritis trials. We have discovered a GM-CSF/CCL17 pathway in monocytes/macrophages. The putative role of this pathway in both inflammatory arthritis and osteoarthritis (OA) pain and disease, including in obesity-associated OA, will be discussed. Ideas on the mode of action of CCL17, including its possible involvement in fibrosis/fibroblast biology, will also be presented. In contrast to the well-recognized chemotactic role of CCL17 (e.g. preferential Th2 cell chemotaxis), these data reveal a lymphocyte-independent, non-chemotactic and algesic role of CCL17 in arthritis and possibly other indications, and suggest that it could be a potential therapeutic target in inflammatory pain and disease.
